Sethy V H, Francis J W, Day J S
J Pharm Pharmacol. 1986 Aug;38(8):631-2. doi: 10.1111/j.2042-7158.1986.tb03099.x.
Binding affinities of adinazolam and its metabolite mono-N-demethyladinazolam, U-42352, to the brain tissue are not altered by the presence of proadifen (SKF-525A) in [3H]flunitrazepam [( 3H]FNZ) binding assays in-vitro. Pretreatment of mice with proadifen significantly blocked the ability of intravenously administered adinazolam to inhibit [3H]FNZ binding in the studies ex-vivo. The binding profile of [3H]FNZ to the brain tissue was not significantly different when animals were treated with U-42352 or proadifen with U-42352. These results suggest that proadifen may block the conversion of adinazolam to its active metabolite U-42352.
在体外[³H]氟硝西泮([³H]FNZ)结合试验中,阿地唑仑及其代谢产物单-N-去甲基阿地唑仑(U-42352)与脑组织的结合亲和力不会因丙磺舒(SKF-525A)的存在而改变。在体内研究中,用丙磺舒预处理小鼠可显著阻断静脉注射阿地唑仑抑制[³H]FNZ结合的能力。当动物用U-42352或丙磺舒与U-42352联合处理时,[³H]FNZ与脑组织的结合谱无显著差异。这些结果表明,丙磺舒可能会阻断阿地唑仑向其活性代谢产物U-42352的转化。